MarketResearchNest.com adds “Anesthetic Effect – Pipeline Review, H2 2017” new report to its research database. The report spread across in 88 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect – Pipeline Review, H2 2017, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.
Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=260058
The Anesthetic Effect (Central Nervous System) pipeline guide
List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,
List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017
Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
4P Therapeutics LLC, Biolab Farmaceutica Ltda, Crescita Therapeutics Inc, Drawbridge Pharmaceuticals Pty Ltd, Expanesthetics Inc, Jiangsu Hengrui Medicine Co Ltd, Lee’s Pharmaceutical Holdings Ltd, Lipicard Technologies Ltd, Paion AG, Phosphagenics Ltd, Physica Pharma, Primex Pharmaceuticals Oy, Proteus SA, Recro Pharma Inc, Taiwan Liposome Company Ltd, The Medicines Company
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=260058
Featured News & Press Releases
Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia
Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015
Sep 01, 2015: Recently Published Study Shows Positive Results for ZiNGO in Pediatric Patients
Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
Nov 05, 2014: Paion’s Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion
Reasons to buy:
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=260058
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain